ICOMS Flowmaker®
Advanced Heart Failure
First-In-Human (FIH)Active
Key Facts
About FineHeart
FineHeart, founded in 2010, is a French private medtech company pioneering a novel implantable heart pump, the ICOMS Flowmaker®, for patients with advanced heart failure. The company has achieved significant milestones, including securing substantial financing (€83M total, with a €35M Series C first close), being named the lead partner of a major European IPCEI project (Tech4Cure), and receiving regulatory authorization in Slovenia to commence its First-In-Human clinical study. Positioned as a potential European leader in Active Implantable Medical Devices (AIMDs), FineHeart is advancing a potentially disruptive technology through clinical development with strong institutional and European Union support.
View full company profileTherapeutic Areas
Other Advanced Heart Failure Drugs
| Drug | Company | Phase |
|---|---|---|
| Engineered Human Myocardium (EHM) Patch | Repairon | Phase 1 |